Progress in Hepatocellular Carcinoma Treatment
Editat de K. Okitaen Limba Engleză Hardback – 30 noi 1999
Toate formatele și edițiile | Preț | Express |
---|---|---|
Paperback (1) | 706.04 lei 6-8 săpt. | |
Springer – 22 oct 2012 | 706.04 lei 6-8 săpt. | |
Hardback (1) | 660.65 lei 39-44 zile | |
Springer – 30 noi 1999 | 660.65 lei 39-44 zile |
Preț: 660.65 lei
Preț vechi: 695.42 lei
-5% Nou
Puncte Express: 991
Preț estimativ în valută:
126.45€ • 131.51$ • 105.96£
126.45€ • 131.51$ • 105.96£
Carte tipărită la comandă
Livrare economică 10-15 martie
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9784431702573
ISBN-10: 4431702571
Pagini: 120
Ilustrații: XI, 107 p.
Dimensiuni: 155 x 235 x 12 mm
Greutate: 0.35 kg
Ediția:2000
Editura: Springer
Colecția Springer
Locul publicării:Tokyo, Japan
ISBN-10: 4431702571
Pagini: 120
Ilustrații: XI, 107 p.
Dimensiuni: 155 x 235 x 12 mm
Greutate: 0.35 kg
Ediția:2000
Editura: Springer
Colecția Springer
Locul publicării:Tokyo, Japan
Public țintă
ResearchDescriere
According to a recent report from the Japanese Ministry of Health and Welfare, the mortality rate for hepatocellular carcinoma (HCC) is more than 30 per 100000 pop ulation. In addition,epidemiologists predictan increase in this figure by the year 2015, because of the rather high incidence of chronic liver diseases caused by HCY. The same situation has been observed in other Asian countries. It seems that HCC is likely to be an endemic disease, because of the higher preva lence of chronic hepatitis and liver cirrhosis caused by HBV, HCV, and/or aflatoxins in Asian and African countries. We also note that an interesting paper appeared in a recent issue of the New England Journal of Medicine describing the increase in younger HCC patients in the United States as compared with past decades. At present, silent hepatitis C infection is now smoldering in 4 million mostly unsuspecting Americans. Those carriers will be candidates for chronic liver disease, which is a pre disposing factor for the development of HCC. In Europe there are an estimated 5 million carriers. Accordingly, it is important to do all we can to reduce the prevalence of HCC not only in African and Asian countries, but also in the United States and Europe. With this perspective,last year the Japanese Society for Hepatology, in cooperation with the Ministry of Health and Welfare, initiated a national campaign to fight HCC.
Cuprins
The Efficacy of the Ultrasonographic Screening Test for Early Detection of Hepatocellular Carcinoma and Risk Factors of HCC in Korea.- Percutaneous Ethanol Injection Therapy, Percutaneous Infarction Therapy, and Percutaneous Microwave Coagulation Therapy for Hepatocellular Carcinoma.- Percutaneous Microwave Coagulation Therapy for Hepatocellular Carcinoma.- Percutaneous Ablation of Hepatocellular Carcinoma.- Treatment with Subsegmental Transcatheter Arterial Embolization for Hepatocellular Carcinoma: Prognosis, Recurrence, and Effect on Liver Function.- Clinical Significance of Liposome-Encapsulated OK-432 Injection with Simultaneous Interventional Radiological Treatment of Hepatocellular Carcinoma Based on Experimental Analysis of Liver-Associated Lymphocytes.- Phase II Trial of Hepatic Arterial Infusion Chemotherapy Using Cisplatin and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma.- Surgical Treatment of Hepatocellular Carcinoma.- Transjugular Intrahepatic Portosystemic Shunt for Patients with Hepatocellular Carcinoma.- Prevention of Hepatocarcinogenesis by Fibrosuppression.- Cancer Vaccination by B7-1-Transfected Hepatocellular Carcinoma Cells.- Clonal Deletion, A Novel Strategy of Cancer Control that Falls Between Cancer Chemoprevention and Cancer Chemotherapy: A Clinical Experience in Liver Cancer.
Caracteristici
New therapeutic modalities in hepatocelluar carcinoma